Share on StockTwits
 

Ultragenyx Pharmaceutical (NASDAQ:RARE) Insider Fmr Llc purchased 175,000 shares of the stock on the open market in a transaction that occurred on Friday, January 31st. The shares were purchased at an average cost of $21.00 per share, with a total value of $3,675,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down 0.50% on Wednesday, hitting $36.08. The stock had a trading volume of 296,466 shares. Ultragenyx Pharmaceutical has a 1-year low of $35.00 and a 1-year high of $47.99. The stock has a 50-day moving average of $38.31 and a 200-day moving average of $38.31. The company’s market cap is $1.015 billion.

Ultragenyx Pharmaceutical Inc is a development-stage biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.